- CONTACT US
- AFS
- Business
- Bussiness
- Car
- Career
- Celebrity
- Digital Products
- Education
- Entertainment
- Fashion
- Film
- Food
- Games
- General Health
- Health
- Health Awareness
- Healthy
- Healthy Lifestyle
- History Facts
- Household Appliances
- Internet
- Investment
- Law
- Lifestyle
- Loans&Mortgages
- Luxury Life Style
- movie
- Music
- Nature
- News
- Opinion
- panorama
- Pet
- Plant
- Politics
- promis
- Recommends
- Science
- Self-care
- services
- Smart Phone
- sport
- Sports
- Style
- Technology
- tire
- Travel
- US
- World

Drugs like Ozempic and Wegovy have had a meteoric rise in recent years, with benefits like weight loss and help with other health issues. But according to a recent study, those benefits fade within two years of patients stopping their treatment.
According to a study published in the BMJ, data from 9,341 obese or overweight patients treated in 37 studies with any of 18 different weight-loss drugs showed that they regained about one pound on average after stopping the drugs.
The same study said they were projected to return to their pre-treatment weight in about two years.
But weight was not the only thing that was projected to return after stopping the treatment. According to the same study, health risk factors like blood pressure and cholesterol levels, which saw benefits while taking the drugs, were projected to return to their old levels within 1.4 years.
GLP-1 medications tested as well
About half of the patients studied took newer GLP-1 drugs like semaglutide, sold as Ozempic and Wegovy, as well as tirzepatide, which is sold as Mounjaro and Zepbound. According to the study, the weight regain rate was faster for these drugs, with an average of 1.8 pounds per month.
“But because people on semaglutide or tirzepatide lose more weight in the first place, they all end up returning to baseline at approximately the same time,” study senior researcher Dimitrios Koutoukidis of Oxford University told Reuters.
Weight loss drugs have shown some success
Weight loss drugs like the ones tested in the study have shown large levels of success in the United States in recent years. Back in October 2025, a survey from the Gallup National Health and Well-Being Index showed that there were an estimated 7.6 million fewer obese people in the United States compared to 2022.
In 2022, the U.S. adult obesity rate was a record-high 39.9%, while in 2025, that rate gradually declined to 37%. While the obesity rate dropped, the usage of GLP-1 drugs like Ozempic and Wegovy doubled between 2025 and 2024, according to the same study.
Contributing: Nicole Fallert, USA TODAY; Reuters
Fernando Cervantes Jr. is a trending news reporter for USA TODAY. Reach him at [email protected] and follow him on X @fern_cerv_.
This article originally appeared on USA TODAY: Here's how fast you can gain weight after ending GLP-1, per study
NEUESTE BEITRÄGE
- 1
RFK Jr. says fewer flu shots for kids may be 'better.' What experts say. - 2
I served on the expert committee that advised the government on new dietary guidelines – most of our recommendations were ignored - 3
Former GLP-1 users regain lost weight after about 18 months, study says - 4
They want better health care — so they're turning to crypto startups - 5
RFK Jr.'s diet guidelines emphasize red meat, full-fat dairy. How healthy are they?
Ähnliche Artikel
Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list
Mobility exercises are an important part of fitness as we age. Here are some tips
How effective is the flu shot this year? New report shows promising results
RFK Jr. releases new dietary guidelines with emphasis on protein, full-fat dairy
OpenAI launches ChatGPT Health to connect medical records, wellness apps
New dietary guidelines recommend more dairy, meat and fats: What to know
Flu activity in US could continue to rise for weeks, top CDC epidemiologist says
Flu surges across U.S. as doctor visits reach highest level since 1997
5 things for parents to know about changes to kids vaccine schedule
Flu cases skyrocket in US. See cases, where people got sick.














